Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Seed VC | Alive

Total Raised


Last Raised

$100K | 5 yrs ago

About Bioharmony Therapeutics

Bioharmony Therapeutics is a biopharmaceutical company focused on the discovery and development of lysin-based antimicrobial therapeutics for patients with multi-drug resistant Gram-negative bacterial infections. Bioharmony's portfolio includes a line-up of lysin-based antimicrobials that target the deadliest infections caused by Gram-negative bacteria.

Bioharmony Therapeutics Headquarters Location

New York,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bioharmony Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bioharmony Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items

Latest Bioharmony Therapeutics News

Bioharmony Therapeutics and Boehringer Ingelheim collaborate to advance bacteriophage lysin therape...

Feb 15, 2019

Source: CBNB 2019/02/15 Source: Company press release, 15 Jan 2019 , 15 Jan 2019 , Website: Bioharmony Therapeutics Inc, a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, announced on 15 Jan 2019 that it has entered into a Collaborative Research and Licensing Agreement with Boehringer Ingelheim to develop bacteriophage lysins for the treatment of multidrug resistant (MDR) Acinetobacter infections, a frequent cause of hospital-acquired pneumonia and life-threatening blood or wound infections. Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of a faculty member at The Rockefeller University. Recently, the World Health Organization listed drug-resistant Acinetobacter baumannii to be a critical priority pathogen, causing around 9% of all bacterial infections in intensive care worldwide against which there are few treatment options available. Financial terms are not disclosed. Original Source: Bioharmony Therapeutics Inc, 2019. From website: Released to ICIS 15 Feb 2019[This article was prepared by Chemical Business NewsBase (CBNB), a third party premium option available through ICIS news. For any queries about the content please contact: John Godfrey,, +44 (0) 1223 463167] SHARE THIS STORY

Bioharmony Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Bioharmony Therapeutics Rank

  • What is Bioharmony Therapeutics's latest funding round?

    Bioharmony Therapeutics's latest funding round is Seed VC.

  • How much did Bioharmony Therapeutics raise?

    Bioharmony Therapeutics raised a total of $100K.

  • Who are the investors of Bioharmony Therapeutics?

    Investors of Bioharmony Therapeutics include Accelerate NY Seed Fund.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.